| http://dbpedia.org/ontology/abstract
|
Portola Pharmaceuticals is an American cli … Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies. Founded and headquartered in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index. In May 2020, Alexion Pharmaceuticals and Portola announced that they had entered into a definitive merger agreement for Alexion to acquire Portola. agreement for Alexion to acquire Portola.
, Portola Pharmaceuticals ist ein US-amerika … Portola Pharmaceuticals ist ein US-amerikanisches, biotechnologisches Pharmaunternehmen, das 2003 in Delaware gegründet wurde und an der amerikanischen Technologiebörse NASDAQ unter dem Kennzeichen PTLA gelistet ist. Seinen Hauptsitz hat Portola in San Francisco, CA. Das Unternehmen ist spezialisiert auf die Entdeckung, Entwicklung und Vermarktung neuartiger Therapeutika aus den Bereichen Thrombose und anderen hämatologischen Erkrankungen. und anderen hämatologischen Erkrankungen.
|
| http://dbpedia.org/ontology/fate
|
Acquired byAlexion Pharmaceuticals
|
| http://dbpedia.org/ontology/foundingYear
|
2003
|
| http://dbpedia.org/ontology/industry
|
http://dbpedia.org/resource/Pharmaceutical_company +
|
| http://dbpedia.org/ontology/keyPerson
|
http://dbpedia.org/resource/Chief_Executive_Officer +
|
| http://dbpedia.org/ontology/location
|
http://dbpedia.org/resource/South_San_Francisco%2C_California +
|
| http://dbpedia.org/ontology/numberOfEmployees
|
324
|
| http://dbpedia.org/ontology/product
|
http://dbpedia.org/resource/Betrixaban +
, http://dbpedia.org/resource/Cerdulatinib +
, http://dbpedia.org/resource/Andexxa +
|
| http://dbpedia.org/ontology/revenue
|
40130.0
|
| http://dbpedia.org/ontology/type
|
http://dbpedia.org/resource/Public_company +
|
| http://dbpedia.org/ontology/wikiPageID
|
58943905
|
| http://dbpedia.org/ontology/wikiPageLength
|
6270
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1122471398
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Rivaroxaban +
, http://dbpedia.org/resource/Chief_Executive_Officer +
, http://dbpedia.org/resource/Recombinant_DNA +
, http://dbpedia.org/resource/Thrombosis +
, http://dbpedia.org/resource/Orphan_drug +
, http://dbpedia.org/resource/NASDAQ_Biotechnology_Index +
, http://dbpedia.org/resource/Daiichi_Sankyo +
, http://dbpedia.org/resource/Peripheral_T-cell_lymphoma +
, http://dbpedia.org/resource/Category:American_companies_established_in_2003 +
, http://dbpedia.org/resource/Cerdulatinib +
, http://dbpedia.org/resource/Category:2013_initial_public_offerings +
, http://dbpedia.org/resource/Janus_kinase +
, http://dbpedia.org/resource/Category:2020_mergers_and_acquisitions +
, http://dbpedia.org/resource/Tumors_of_the_hematopoietic_and_lymphoid_tissues +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_of_the_United_States +
, http://dbpedia.org/resource/Novartis +
, http://dbpedia.org/resource/Antidote +
, http://dbpedia.org/resource/Public_company +
, http://dbpedia.org/resource/Category:Companies_formerly_listed_on_the_Nasdaq +
, http://dbpedia.org/resource/Initial_public_offering +
, http://dbpedia.org/resource/Janssen_Pharmaceutica +
, http://dbpedia.org/resource/Andexanet_alfa +
, http://dbpedia.org/resource/Pharmaceutical_company +
, http://dbpedia.org/resource/Pharmaceutical_drug +
, http://dbpedia.org/resource/Bayer +
, http://dbpedia.org/resource/Pfizer +
, http://dbpedia.org/resource/European_Commission +
, http://dbpedia.org/resource/Gaspar_de_Portol%C3%A0 +
, http://dbpedia.org/resource/Russell_2000_Index +
, http://dbpedia.org/resource/NASDAQ +
, http://dbpedia.org/resource/Syk +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Millennium_Pharmaceuticals +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_established_in_2003 +
, http://dbpedia.org/resource/P2Y12 +
, http://dbpedia.org/resource/Bristol-Myers_Squibb +
, http://dbpedia.org/resource/Category:Companies_based_in_San_Francisco +
, http://dbpedia.org/resource/Elinogrel +
, http://dbpedia.org/resource/Direct_Xa_inhibitor +
, http://dbpedia.org/resource/Committee_for_Medicinal_Products_for_Human_Use +
, http://dbpedia.org/resource/Alexion_Pharmaceuticals +
, http://dbpedia.org/resource/FDA +
, http://dbpedia.org/resource/San_Francisco_Bay +
, http://dbpedia.org/resource/South_San_Francisco%2C_California +
, http://dbpedia.org/resource/Betrixaban +
, http://dbpedia.org/resource/Apixaban +
, http://dbpedia.org/resource/Andexxa +
, http://dbpedia.org/resource/New_oral_anticoagulants +
|
| http://dbpedia.org/property/areaServed
|
Worldwide
|
| http://dbpedia.org/property/fate
|
Acquired by Alexion Pharmaceuticals
|
| http://dbpedia.org/property/foundation
|
2003
|
| http://dbpedia.org/property/founders
|
Charles J. Homcy, David R. Philips
|
| http://dbpedia.org/property/industry
|
http://dbpedia.org/resource/Pharmaceutical_company +
|
| http://dbpedia.org/property/keyPeople
|
Scott Garland
|
| http://dbpedia.org/property/location
|
South San Francisco, California, United States
|
| http://dbpedia.org/property/name
|
Portola Pharmaceuticals
|
| http://dbpedia.org/property/numEmployees
|
324
|
| http://dbpedia.org/property/products
|
http://dbpedia.org/resource/Cerdulatinib +
, http://dbpedia.org/resource/Betrixaban +
, http://dbpedia.org/resource/Andexxa +
|
| http://dbpedia.org/property/revenue
|
40130.0
|
| http://dbpedia.org/property/subsid
|
Portola Pharma UK Limited
|
| http://dbpedia.org/property/type
|
http://dbpedia.org/resource/Public_company +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Ubl +
, http://dbpedia.org/resource/Template:Authority_control +
, http://dbpedia.org/resource/Template:URL +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:COI +
, http://dbpedia.org/resource/Template:Infobox_company +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Pharmaceutical_companies_established_in_2003 +
, http://dbpedia.org/resource/Category:2013_initial_public_offerings +
, http://dbpedia.org/resource/Category:2020_mergers_and_acquisitions +
, http://dbpedia.org/resource/Category:Pharmaceutical_companies_of_the_United_States +
, http://dbpedia.org/resource/Category:American_companies_established_in_2003 +
, http://dbpedia.org/resource/Category:Companies_based_in_San_Francisco +
, http://dbpedia.org/resource/Category:Companies_formerly_listed_on_the_Nasdaq +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Portola_Pharmaceuticals?oldid=1122471398&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Portola_Pharmaceuticals +
|
| http://xmlns.com/foaf/0.1/name
|
Portola Pharmaceuticals
|
| owl:sameAs |
http://de.dbpedia.org/resource/Portola_Pharmaceuticals +
, http://arz.dbpedia.org/resource/%D8%A8%D9%88%D8%B1%D8%AA%D9%88%D9%84%D8%A7_%D9%84%D9%84%D8%A7%D8%AF%D9%88%D9%8A%D9%87 +
, https://global.dbpedia.org/id/2ocKc +
, http://www.wikidata.org/entity/Q30269199 +
, http://dbpedia.org/resource/Portola_Pharmaceuticals +
|
| rdf:type |
http://www.wikidata.org/entity/Q24229398 +
, http://dbpedia.org/ontology/Agent +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#Agent +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#SocialPerson +
, http://dbpedia.org/ontology/Company +
, http://dbpedia.org/ontology/Organisation +
, http://schema.org/Organization +
, http://www.wikidata.org/entity/Q43229 +
, http://www.wikidata.org/entity/Q4830453 +
|
| rdfs:comment |
Portola Pharmaceuticals is an American cli … Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops, and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies. Founded and headquartered in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index. In May 2020, Alexion Pharmaceuticals and Portola announced that they had entered into a definitive merger agreement for Alexion to acquire Portola. agreement for Alexion to acquire Portola.
, Portola Pharmaceuticals ist ein US-amerika … Portola Pharmaceuticals ist ein US-amerikanisches, biotechnologisches Pharmaunternehmen, das 2003 in Delaware gegründet wurde und an der amerikanischen Technologiebörse NASDAQ unter dem Kennzeichen PTLA gelistet ist. Seinen Hauptsitz hat Portola in San Francisco, CA. Das Unternehmen ist spezialisiert auf die Entdeckung, Entwicklung und Vermarktung neuartiger Therapeutika aus den Bereichen Thrombose und anderen hämatologischen Erkrankungen. und anderen hämatologischen Erkrankungen.
|
| rdfs:label |
Portola Pharmaceuticals
|
